Roche Annual General Meeting 2026

• Shareholders approved all proposals of the Board of Directors 
• Severin Schwan re-elected as Chairman of the Board of Directors; all other Board members standing for election were confirmed
• 39th consecutive dividend increase to CHF 9.80 per share
• Exchange of non-voting equity securities (Genussscheine) for Participation Certificates approved

Basel, 10 March 2026 – Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that its shareholders approved all proposals of the Board of Directors at its Annual General Meeting. The 594 shareholders in attendance, who represented 77,22% of the total 106,691,000 shares, approved the Annual Financial Statements and Consolidated Financial Statements for 2025, the Remuneration Report and the Sustainability Report for 2025.

Dr Severin Schwan was re-elected as Chairman of the Board of Directors by 97,75% of the votes. Addressing the shareholders in a speech, he said:

“The past year was a very successful one for Roche. With our long-term focus, we at Roche are on track — scientifically, financially, and strategically. By combining our expertise in Diagnostics and Pharmaceuticals under one roof, we will continue to have a competitive advantage in the future — one that benefits millions of patients around the world.”

In addition, the shareholders approved an increase in the dividend for the past financial year to 9.80 Swiss francs (gross) per share and non-voting equity security. This is the 39th consecutive dividend increase. The shareholders also authorised the discharge of the members of the Board of Directors and the Corporate Executive Committee.

The shareholders approved the total bonuses of the Corporate Executive Committee for the 2025 financial year by 95,18% of votes. They also approved a maximum total future remuneration by 94,77% of votes for the Board of Directors and by 90,18% of votes for the Corporate Executive Committee until the 2027 Annual General Meeting.

In addition to Severin Schwan, all other members of the Board of Directors were re-elected to the Board of Directors for a one-year term:

• Mr André Hoffmann
• Dr Jörg Duschmalé
• Dr Patrick Frost
• Ms Anita Hauser
• Professor Dr Akiko Iwasaki
• Professor Dr Richard P. Lifton
• Dr Jemilah Mahmood
• Dr Mark Schneider

Additionally, Lubomira Rochet was elected to the Board of Directors for a one-year term.